| KDM5 histone demethylase activity links cellular transcriptomic heterogeneity to therapeutic resistance K Hinohara, HJ Wu, S Vigneau, TO McDonald, KJ Igarashi, KN Yamamoto, ... Cancer cell 34 (6), 939-953. e9, 2018 | 184 | 2018 |
| Cbl and human myeloid neoplasms: the Cbl oncogene comes of age SC Kales, PE Ryan, MM Nau, S Lipkowitz Cancer research 70 (12), 4789-4794, 2010 | 140 | 2010 |
| An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19 JH Shrimp, SC Kales, PE Sanderson, A Simeonov, M Shen, MD Hall bioRxiv, 2020 | 124 | 2020 |
| CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases YHC Tan, S Krishnaswamy, S Nandi, R Kanteti, S Vora, K Onel, R Hasina, ... PloS one 5 (1), e8972, 2010 | 118 | 2010 |
| KDM5 histone demethylases repress immune response via suppression of STING L Wu, J Cao, WL Cai, SM Lang, JR Horton, DJ Jansen, ZZ Liu, JF Chen, ... PLoS biology 16 (8), e2006134, 2018 | 111 | 2018 |
| Structural basis for KDM5A histone lysine demethylase inhibition by diverse compounds JR Horton, X Liu, M Gale, L Wu, JR Shanks, X Zhang, PJ Webber, ... Cell chemical biology 23 (7), 769-781, 2016 | 94 | 2016 |
| An OpenData portal to share COVID-19 drug repurposing data in real time KR Brimacombe, T Zhao, RT Eastman, X Hu, K Wang, M Backus, ... bioRxiv, 2020 | 74 | 2020 |
| Assay guidance manual [Internet] S Markossian, A Grossman, K Brimacombe, M Arkin, D Auld, C Austin, ... Eli Lilly & Company and the National Center for Advancing Translational Sciences, 2004 | 63 | 2004 |
| KDM5B promotes drug resistance by regulating melanoma-propagating cell subpopulations X Liu, SM Zhang, MK McGeary, I Krykbaeva, L Lai, DJ Jansen, SC Kales, ... Molecular cancer therapeutics 18 (3), 706-717, 2019 | 51 | 2019 |
| High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2 NP Coussens, SC Kales, MJ Henderson, OW Lee, KY Horiuchi, Y Wang, ... Journal of Biological Chemistry 293 (35), 13750-13765, 2018 | 50 | 2018 |
| Major histocompatibility class II genes in rainbow trout (Oncorhynchus mykiss) exhibit temperature dependent downregulation S Nath, S Kales, K Fujiki, B Dixon Immunogenetics 58, 443-453, 2006 | 49 | 2006 |
| Molecular cloning and characterization of calreticulin from rainbow trout (Oncorhynchus mykiss) S Kales, K Fujiki, B Dixon Immunogenetics 55, 717-723, 2004 | 47 | 2004 |
| Response of the rainbow trout monocyte/macrophage cell line, RTS11 to the water molds Achlya and Saprolegnia SC Kales, SJ DeWitte-Orr, NC Bols, B Dixon Molecular immunology 44 (9), 2303-2314, 2007 | 45 | 2007 |
| Assay Guidance Manual: Quantitative Biology and Pharmacology in Preclinical Drug Discovery NP Coussens, GS Sittampalam, R Guha, K Brimacombe, A Grossman, ... Clinical and translational science 11 (5), 461-470, 2018 | 44 | 2018 |
| A Cell Line (HEW) from Embryos of Haddock (Melanogrammus aeglefinius) and Its Capacity to Tolerate Environmental Extremes SP Bryson, EM Joyce, DJ Martell, LEJ Lee, SE Holt, SC Kales, K Fujiki, ... Marine Biotechnology 8, 641-653, 2006 | 41 | 2006 |
| Calreticulin in rainbow trout: a limited response to endoplasmic reticulum (ER) stress SC Kales, NC Bols, B Dixon Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular …, 2007 | 38 | 2007 |
| Beta-2-microglobulin gene expression is maintained in rainbow trout and Atlantic salmon kept at low temperatures S Kales, J Parks-Dely, P Schulte, B Dixon Fish & shellfish immunology 21 (2), 176-186, 2006 | 36 | 2006 |
| Balancing protein stability and activity in cancer: a new approach for identifying driver mutations affecting CBL ubiquitin ligase activation M Li, SC Kales, K Ma, BA Shoemaker, J Crespo-Barreto, AL Cangelosi, ... Cancer research 76 (3), 561-571, 2016 | 35 | 2016 |
| KDM5 histone demethylase activity links cellular transcriptomic heterogeneity to therapeutic resistance K Hinohara, HJ Wu, S Vigneau, TO McDonald, KJ Igarashi, KN Yamamoto, ... Cancer cell 35 (2), 330-332, 2019 | 32 | 2019 |
| Structure-based engineering of irreversible inhibitors against histone lysine demethylase KDM5A JR Horton, CB Woodcock, Q Chen, X Liu, X Zhang, J Shanks, G Rai, ... Journal of medicinal chemistry 61 (23), 10588-10601, 2018 | 32 | 2018 |
